MarketBeat
18 Aug 2026, 07:02 UTC · 2h ago
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
18 Aug 2026, 07:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
TONMYA second-quarter net sales were $11 million, approximately triple the first-quarter sales. — Strong early revenue growth for a newly launched product indicates positive market adoption and commercial viability.
+0.60Tonix is expanding its sales force from 100 to 150 representatives, with full deployment expected in September. — Aggressive expansion of the sales force suggests company confidence in demand and a push for higher market penetration.
+0.40The company has secured commercial contracts with two of the three major pharmacy benefit managers (PBMs). — PBM access is a critical hurdle for drug commercialization; securing majority coverage reduces barriers to patient access.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Tonix expects to initiate a Phase 2 field study for the Lyme disease prevention antibody TNX-4800 in Q1, following a positive FDA meeting. — Positive FDA alignment and a clear timeline for a large-scale study (3,300 people) provide a tangible pipeline catalyst.
+0.20A Phase 2 study for TONMYA in major depressive disorder is underway, with results expected in early 2028. — Label expansion represents long-term growth potential, but the timeline is too distant to drive immediate price action.
+0.10Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3d ago
